$AXGT News
Last published 5y ago
- 5y agoAXGTSIOXSio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific AdvisorGlobeNewswireA pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapyDr. Gao recently served as President of the American Society for Gene and...
- 5y agoAXGTSIOXSio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020GlobeNewswireContinued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseasesCompleted rebranding to Sio Gene Therapies as part of...
- 6y agoAXGTAxovant Gene Therapies Announces Name Change to Sio Gene TherapiesGlobeNewswireRebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicinesCompany’s common stock will trade on the NASDAQ...
- 6y agoAXGTAxovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff DiseasesGlobeNewswireAXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseasesRepresents Axovant’s second IND clearance for a gene therapy program in the last 12...
- 6y agoAXGTAxovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020GlobeNewswirePatient-level data in cohort 2 of SUNRISE-PD study demonstrates consistent, clinically meaningful outcomes and evidence of dose responseDelays in manufacturing process expected to postpone the start...
- 6y agoONCYSELBAXGTCRDF+1Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few YearsPR NewswireEvery year, the number of cancer-related deaths caused due to gastric cancer has been reaching to more than 800,000, as per the records of the World...
- 6y agoAXGTAxovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020GlobeNewswireAgenda to feature presentations from leading clinical researchers in Parkinson’s disease and the Michael J. Fox FoundationIndividual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study to...
- 6y agoAXGTAxovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff DiseaseGlobeNewswireNEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that...
- 6y agoAXGTAxovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 GangliosidosisGlobeNewswireNEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that...
- 6y agoAXGTAxovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial OfficerGlobeNewswireKristiina Vuori, M.D., Ph.D. is a leading genetics and cancer researcher who serves as President and Board member of Sanford Burnham Prebys Medical Discovery InstituteAppointment of Dr. Vuori...
- 6y agoAXGTAxovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene TherapyGlobeNewswire• AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months• 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding...
- 6y agoAXGTAxovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6thGlobeNewswireNEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present...
- 6y agoAXGTAxovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing PartnershipGlobeNewswirePartnership secures access to cGMP capacity and resources at Viralgen to support the development and commercialization of Axovant’s AAV gene therapy programs for GM1 and GM2 gangliosidosisPartnership...
- 6y agoAXGTAxovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"GlobeNewswire- Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists NEW YORK and BASEL, Switzerland,...
- 6y agoAXGTAxovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020GlobeNewswireData readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PDCompany had $55.5 million of cash...
- 6y agoAXGTAxovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PDGlobeNewswireNEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases,...
- 6y agoAXGTAxovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020GlobeNewswireCompleted enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020Completed enrollment of low-dose cohort of Phase 1/2...
- 6y agoAXGTAxovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 GangliosidosisGlobeNewswire- Six-month data from low-dose cohort expected in Q4 2020- IND amended to include Type I (infantile onset) patients and to evaluate a higher dose- Expect to initiate high-dose cohort in 2H 2020 ...
- 6y agoAXGTAxovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswireNEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public...
- 6y agoAXGTAxovant Gene Therapies Announces Pricing of $65 Million Public OfferingGlobeNewswireNEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of...
- 6y agoAXGTAxovant Gene Therapies Announces Commencement of Public OfferingGlobeNewswireNEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its...
- 6y agoAXGTAxovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019GlobeNewswireNEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial...
- 6y agoAXGTAxovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline ProgramsGlobeNewswireNEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...
- 6y agoAXGTAxovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 GangliosidosisGlobeNewswireNEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single...
- 6y agoAXGTAxovant Announces Amendment to Credit Facility with Hercules CapitalGlobeNewswireNEW YORK and BASEL, Switzerland, Dec. 03, 2019 (GLOBE NEWSWIRE) -- New loan amendment reduces loan obligation by 50% without penalty, eliminates minimum cash covenant, and extends interest-only...
- 7y agoAXGTAxovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019GlobeNewswireFirst evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019Continued enrollment of patients in AXO-AAV-GM1...
- 7y agoAXGTAxovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019GlobeNewswireNEW YORK and BASEL, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that...
- 7y agoAXGTAxovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual CongressGlobeNewswireNEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced...
- 7y agoAXGTAxovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the MesaGlobeNewswireBASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag Meswani,...